Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Halma lifts dividend as profits rise to record high

(Sharecast News) - Safety equipment outfit Halma has reported record revenues and profits for the 12 months to 31 March, with both rising by double-digit percentages, as it lifted its dividend by 7%. The company, which makes hazard detection and life protection equipment, reported revenues of £2.25bn, up 11% over the year, as 18% growth in the Environment and Analysis sectors made up for a more modest 3.2% improvement in Healthcare.

On a regional basis, revenues were higher across all geographies, including double-digit growth in the US and Asia Pacific.

Adjusted earnings before interest and tax were 15% higher at £486m, helped by an improvement in the adjusted EBIT margin to 21.6% from 20.8%.

"Achieving such a strong performance amidst varied market conditions and a challenging economic and geopolitical backdrop is a testament to the fundamental strengths of our Sustainable Growth Model," said chief executive Marc Ronchetti.

"These include our positive purpose and culture, and a diverse portfolio of companies, each with strong positions in their markets and growth underpinned by long-term drivers."

The company declared a final dividend of 14.2p per share, taking the full-year payout to 23.12p, up from 21.61p previously.

The new financial year has started positively, Halma said, with a strong order book and order intake ahead of last year.

The company pointed to organic revenue growth at constant currencies in the upper single-digit percentage range, with adjusted EBIT margins expected to be above the middle of the 19-23% guidance.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.